Adam Rosenberg
Director/Board Member at ELIEM THERAPEUTICS, INC.
Net worth: 603 759 $ as of 29/04/2024
Network origin in Adam Rosenberg first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts.
72
| Private Company | Investment Managers | 72 |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA.
27
| Operating Division | Investment Managers | 27 |
| Public Company | Biotechnology | 14 | |
Ambagon Therapeutics, Inc.
 Ambagon Therapeutics, Inc. BiotechnologyHealth Technology Ambagon Therapeutics, Inc. provides healthcare services. It specializes in biotechnology. The company is headquartered in San Francisco, CA.
8
| Holding Company | Biotechnology | 8 |
Link Medicine Corp.
 Link Medicine Corp. Pharmaceuticals: MajorHealth Technology Link Medicine Corp. develops disease modifying neurodegenerative therapies. The company was founded by Edward I. Rudman, Peter T. Lansbury, David Neafus and Adam J. Rosenberg in 2005 and is headquartered in Cambridge, MA.
6
| Extinct | Pharmaceuticals: Major | 6 |
Sionna Therapeutics, Inc.
 Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan.
6
| Holding Company | Medical/Nursing Services | 6 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Adam Rosenberg via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Atlas Venture Life Science Advisors LLC
 Atlas Venture Life Science Advisors LLC Investment ManagersFinance Atlas Venture Life Science Advisors LLC (Atlas Venture) is a venture capital firm founded in 2014. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor Private Equity Investor Private Equity Investor Private Equity Investor Consultant / Advisor Consultant / Advisor Private Equity Investor Consultant / Advisor Consultant / Advisor | |
Nimbus Therapeutics LLC
 Nimbus Therapeutics LLC BiotechnologyHealth Technology Nimbus Therapeutics LLC provides drug discovery research services. It is a computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. The company was founded by Bruce Lee Booth in 2009 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Founder Director/Board Member Corporate Officer/Principal Consultant / Advisor Chief Operating Officer Chief Executive Officer Chief Executive Officer Private Equity Investor | |
| KYMERA THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member Founder Director/Board Member Director/Board Member Director/Board Member Founder Private Equity Investor | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree Doctorate Degree Undergraduate Degree Doctorate Degree Doctorate Degree | |
| BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Director/Board Member Corporate Officer/Principal Corporate Officer/Principal Private Equity Investor Corporate Officer/Principal | |
Disarm Therapeutics, Inc.
 Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | Biotechnology | Chief Executive Officer Consultant / Advisor Founder Private Equity Investor Corporate Officer/Principal Chief Tech/Sci/R&D Officer Private Equity Investor | |
| GENERATION BIO CO. | Pharmaceuticals: Major | Founder Chief Executive Officer Chief Tech/Sci/R&D Officer Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer | |
| Princeton University | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree Doctorate Degree | |
| THIRD HARMONIC BIO, INC. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member Director/Board Member Director/Board Member Corporate Officer/Principal | |
| Yale University | College/University | Undergraduate Degree Undergraduate Degree Doctorate Degree Doctorate Degree Undergraduate Degree Undergraduate Degree | |
Q32 Bio, Inc.
 Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | Biotechnology | Founder Chairman Founder Chief Executive Officer Founder Consultant / Advisor | |
| SPERO THERAPEUTICS, INC. | Biotechnology | Director/Board Member Founder Director/Board Member Chief Operating Officer Director/Board Member | |
Rectify Pharmaceuticals LLC
 Rectify Pharmaceuticals LLC Miscellaneous Commercial ServicesCommercial Services Rectify Pharmaceuticals LLC is a biotech company that is developing positive functional modulators (PFMs) to address the underlying cause of serious ABC transporter-mediated diseases. The company is based in Cambridge, MA and was founded by Jonathan Moore. The company's team includes Xiaobing Li as Chief Development Officer, Robert Hughes as Executive Vice President of Drug Discovery and Preclinical Development, and Leif-Ann Tuohey as Senior Vice President and Head of Business Development. The company has received $100 million in Series A financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund. The CEO is Rajesh Devraj, who is also a venture partner at Atlas Venture. | Miscellaneous Commercial Services | Chairman Director/Board Member Chief Executive Officer Founder Consultant / Advisor | |
| University of Pennsylvania | College/University | Undergraduate Degree Undergraduate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
HotSpot Therapeutics, Inc.
 HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | Biotechnology | Chairman Consultant / Advisor Founder Founder Corporate Officer/Principal | |
| Harvard Medical School | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Graduate Degree Doctorate Degree | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Director/Board Member | |
Matchpoint Therapeutics, Inc.
 Matchpoint Therapeutics, Inc. BiotechnologyHealth Technology Matchpoint Therapeutics, Inc. is a biotechnology company based in Cambridge, MA. The company aims to discover and develop precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. Matchpoint's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning, and covalent chemistry library evolution. The company was founded by Jianwei Che, Edward Chouchani, Tinghu Zhang, Nathanael S. Gray, and the CEO is G. Andre Turenne. | Biotechnology | Chairman Director/Board Member Chief Executive Officer Chief Invt Officer-Spezialfond | |
| DISC MEDICINE, INC. | Biotechnology | Director/Board Member Director/Board Member Chief Executive Officer Chairman | |
Padlock Therapeutics, Inc.
 Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Director/Board Member Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Private Equity Analyst | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Doctorate Degree Undergraduate Degree Undergraduate Degree | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Private Equity Investor | |
Navitor Pharmaceuticals, Inc.
 Navitor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Navitor Pharmaceuticals, Inc. develops medicine for age-related diseases. Its drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. The company was founded by Alan L. Crane, David Sabatini and David Goldfarb and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Director/Board Member Chief Executive Officer | |
Nimbus Apollo, Inc.
 Nimbus Apollo, Inc. Pharmaceuticals: MajorHealth Technology Nimbus Apollo, Inc. provides drug discovery research services. The company is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member Chief Executive Officer | |
Disc Medicine Opco, Inc.
 Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Chief Executive Officer Chairman Private Equity Investor | |
Arteaus Therapeutics LLC
 Arteaus Therapeutics LLC BiotechnologyHealth Technology Arteaus Therapeutics LLC develops therapies for migraine prevention. The company was founded by Dave Grayzel and Scott C. Chappel on July 15, 2011 and is headquartered in Cambridge, MA. | Biotechnology | Founder Chief Executive Officer Founder Corporate Officer/Principal | |
New England Venture Capital Association, Inc.
 New England Venture Capital Association, Inc. Miscellaneous Commercial ServicesCommercial Services New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
Annovation BioPharma, Inc.
 Annovation BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Annovation BioPharma, Inc. develops pharmaceutical products in the field of anesthesia, sedation and sleep. It is developing a rapid-acting anesthesia called Rapidate. The firm's novel agents are designed to allow more precise control of anesthesia and enable safer treatment of patients undergoing surgical procedures. The company was founded in 2009 by Nicholas Barker and is headquartered in Parsippany, NJ. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Founder Corporate Officer/Principal | |
| TRANSLATE BIO, INC. | Biotechnology | Founder Director/Board Member Director/Board Member Director/Board Member | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| Harvard Business School | College/University | Corporate Officer/Principal Masters Business Admin Masters Business Admin | |
| SURFACE ONCOLOGY, INC. | Biotechnology | Chief Executive Officer Director/Board Member Chief Operating Officer | |
Indalo Therapeutics, Inc.
 Indalo Therapeutics, Inc. BiotechnologyHealth Technology Indalo Therapeutics, Inc. operates as a biopharmaceutical firm that develops integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The company was founded by David Griggs, Williamson Z. Bradford III, Peter Ruminski, and Robert W. Karr and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal President Corporate Officer/Principal | |
| DYNE THERAPEUTICS, INC. | Biotechnology | Founder Chief Executive Officer Chief Tech/Sci/R&D Officer | |
| DYAX CORP. | Pharmaceuticals: Major | Chief Administrative Officer Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Accent Therapeutics, Inc.
 Accent Therapeutics, Inc. BiotechnologyHealth Technology Accent Therapeutics, Inc. operates as a biopharmaceutical company which develops treatments for cancer patients. The company was founded by Howard Y. Chang, Chuan He and Robert A. Copeland in September 2017 and is headquartered in Lexington, MA. | Biotechnology | Director/Board Member Director/Board Member Founder | |
Cadent Therapeutics, Inc.
 Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Chairman Founder Chief Executive Officer | |
Northeastern University
 Northeastern University Other Consumer ServicesConsumer Services Founded in 1898, Northeastern University is a private research university located in the heart of Boston. Northeastern teaches worldwide experiential learning, urban engagement, and interdisciplinary research that meets global and societal needs. The University offers a range of undergraduate and graduate programs leading to degrees through the doctorate in nine colleges and schools. | College/University | Doctorate Degree Masters Business Admin Undergraduate Degree | |
| AEROVATE THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| TENAYA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member Director/Board Member | |
Stromedix, Inc.
 Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Stromedix, Inc. develops novel drugs to treat fibrosis and fibrotic organ failure. The company was founded by Michael Gilman in 2006 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| Imperial College London | College/University | Doctorate Degree Doctorate Degree Undergraduate Degree |
Statistics
International
| United States | 48 |
| United Kingdom | 3 |
Sectoral
| Health Technology | 37 |
| Consumer Services | 9 |
| Commercial Services | 4 |
| Finance | 3 |
Operational
| Director/Board Member | 538 |
| Corporate Officer/Principal | 222 |
| Independent Dir/Board Member | 121 |
| Private Equity Investor | 96 |
| Undergraduate Degree | 87 |
Most connected contacts
| Insiders | |
|---|---|
| Jean-Francois Formela | 47 |
| Bruce Booth | 40 |
| Ryan Moore | 38 |
| Christopher Lynch | 38 |
| Peter Barrett | 38 |
| John Maraganore | 37 |
| Joshua Resnick | 36 |
| Kevin Bitterman | 36 |
| Liam Ratcliffe | 32 |
| Peter Kolchinsky | 32 |
| Roel Bulthuis | 29 |
| Mark Iwicki | 26 |
| Risa Stack | 25 |
| Jason Rhodes | 24 |
| Dave Grayzel | 23 |
- Stock Market
- Insiders
- Adam Rosenberg
- Company connections
